WO2007114959A3 - Altered peptide ligands of gad65 - Google Patents

Altered peptide ligands of gad65 Download PDF

Info

Publication number
WO2007114959A3
WO2007114959A3 PCT/US2007/008980 US2007008980W WO2007114959A3 WO 2007114959 A3 WO2007114959 A3 WO 2007114959A3 US 2007008980 W US2007008980 W US 2007008980W WO 2007114959 A3 WO2007114959 A3 WO 2007114959A3
Authority
WO
WIPO (PCT)
Prior art keywords
gad65
peptide ligands
altered peptide
compositions
islet
Prior art date
Application number
PCT/US2007/008980
Other languages
French (fr)
Other versions
WO2007114959A2 (en
Inventor
Anthony Quinn
Original Assignee
Univ Toledo
Anthony Quinn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toledo, Anthony Quinn filed Critical Univ Toledo
Priority to US12/295,793 priority Critical patent/US7994279B2/en
Publication of WO2007114959A2 publication Critical patent/WO2007114959A2/en
Publication of WO2007114959A3 publication Critical patent/WO2007114959A3/en

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L12/00—Data switching networks
    • H04L12/66—Arrangements for connecting between networks having differing types of switching systems, e.g. gateways

Abstract

Modified GAD65 compositions antagonize the activities of islet-specific T cells that contribute to the progression of one or more autoimmune disorders. The compositions are also antagonistic in humanized mice that express human HLA alleles associated with increased-risk of Type 1 diabetes.
PCT/US2007/008980 2006-04-04 2007-03-30 Altered peptide ligands of gad65 WO2007114959A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/295,793 US7994279B2 (en) 2006-04-04 2007-03-30 Altered peptide ligands of GAD65

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78923606P 2006-04-04 2006-04-04
US60/789,236 2006-04-04

Publications (2)

Publication Number Publication Date
WO2007114959A2 WO2007114959A2 (en) 2007-10-11
WO2007114959A3 true WO2007114959A3 (en) 2008-12-04

Family

ID=38564157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008980 WO2007114959A2 (en) 2006-04-04 2007-03-30 Altered peptide ligands of gad65

Country Status (2)

Country Link
US (1) US7994279B2 (en)
WO (1) WO2007114959A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202210967D0 (en) 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
DE69334246D1 (en) * 1992-12-03 2008-12-24 Univ California IMPROVED REAGENTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES AND STIFF MAN SYNDROME
US5821334A (en) * 1996-01-26 1998-10-13 Vanderbilt University Insulin-dependent diabetes mellitus-specific chimeric polypeptides
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
US6866843B2 (en) * 1999-12-06 2005-03-15 Viacell, Inc. Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
AU2003273577A1 (en) * 2002-05-30 2003-12-19 Sloan Kettering Institute For Cancer Research Suicide tetramers comprising mhc class i and uses thereof
WO2004035084A2 (en) * 2002-10-02 2004-04-29 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
US20050152914A1 (en) * 2003-06-13 2005-07-14 Diamyd, Inc. Formulation of antigen
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARRISON L.C.: "The Prospect of Vaccination to Prevent Type 1 Diabetes", HUMAN VACCINES, vol. 1, no. 4, July 2005 (2005-07-01) - August 2005 (2005-08-01), pages 143 - 150, XP001538915 *
HEIJMANS N. ET AL.: "Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice", J. NEUROIMMUNOL., vol. 167, no. 1-2, 2005, pages 23 - 33, XP005053879 *
MASEWICZ S.A. ET AL.: "Modulation of T cell responses to hGAD65 peptide epitopes", TISSUE ANTIGENS, vol. 9, 2002, pages 101 - 112 *

Also Published As

Publication number Publication date
WO2007114959A2 (en) 2007-10-11
US20090305340A1 (en) 2009-12-10
US7994279B2 (en) 2011-08-09

Similar Documents

Publication Publication Date Title
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
TWI350680B (en) Limiting access to network functions based on personal characteristics of the user
AP2279A (en) Amitraz compositions.
EP1919302B8 (en) Food comprising silicon
WO2007014930A3 (en) Polyammonium/polysiloxane copolymers
WO2007014169A3 (en) Anti-cd26 antibodies and methods of use thereof
EP1812563A4 (en) Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2005119627A3 (en) Personal nutrition control devices
PL1846534T3 (en) Stabilized iodocarbon compositions
ZA200707010B (en) Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidini-3-yl)-isoindole-1-3-dione
NO20080991L (en) Bazedoxifene acetate formulations
WO2008020405A3 (en) Azetidine compounds as orexin receptor antagonists
WO2007073553A3 (en) Block copolymer particles
IL204211A (en) Anti-epha2 antibody, compositions comprising the same and uses thereof
WO2005067887A3 (en) Formulations of ramipril
WO2008150537A3 (en) Silica particles and methods of making and using the same
WO2007009013A3 (en) Methods and compositions related to a braf mutation and microsatellite stability
WO2009058451A3 (en) Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
WO2007114959A3 (en) Altered peptide ligands of gad65
WO2012016026A3 (en) Electrolarynx devices and uses thereof
WO2005122723A3 (en) Compositions and methods that enhance articular cartilage repair
WO2008139325A3 (en) Cluster mounting mechanism
WO2007050950A3 (en) Silicon-urea-azolides, their preparation and use in the preparation of silicones with isocyanate terminal groups

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07775223

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12295793

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 07775223

Country of ref document: EP

Kind code of ref document: A2